Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1963
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1975 1
1980 3
1983 2
1984 1
1985 1
1986 2
1987 2
1988 7
1989 11
1990 5
1991 8
1992 5
1993 11
1994 13
1995 10
1996 8
1997 9
1998 6
1999 10
2000 18
2001 14
2002 13
2003 10
2004 14
2005 22
2006 21
2007 26
2008 21
2009 14
2010 22
2011 26
2012 41
2013 32
2014 27
2015 29
2016 41
2017 42
2018 41
2019 49
2020 91
2021 64
2022 65
2023 58
2024 76
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

902 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis and Treatment of AL Amyloidosis.
Palladini G, Milani P. Palladini G, et al. Drugs. 2023 Feb;83(3):203-216. doi: 10.1007/s40265-022-01830-z. Epub 2023 Jan 18. Drugs. 2023. PMID: 36652193 Review.
Systemic light chain (AL) amyloidosis is caused by an usually small B cell clone that produces a toxic light chain forming amyloid deposits in tissue. ...The diagnosis requires demonstration in a tissue biopsy of amyloid deposits formed b …
Systemic light chain (AL) amyloidosis is caused by an usually small B cell clone that produces a toxic light
Systemic amyloidosis.
Wechalekar AD, Gillmore JD, Hawkins PN. Wechalekar AD, et al. Lancet. 2016 Jun 25;387(10038):2641-2654. doi: 10.1016/S0140-6736(15)01274-X. Epub 2015 Dec 21. Lancet. 2016. PMID: 26719234 Review.
This Seminar focuses on changes in their epidemiology, the current approach to diagnosis, and advances in treatment. Systemic light chain (AL) amyloidosis is the most common of these conditions, but wild-type transthyretin cardiac amyloidosis (A …
This Seminar focuses on changes in their epidemiology, the current approach to diagnosis, and advances in treatment. Systemic light
When to Suspect a Diagnosis of Amyloidosis.
Vaxman I, Gertz M. Vaxman I, et al. Acta Haematol. 2020;143(4):304-311. doi: 10.1159/000506617. Epub 2020 Apr 27. Acta Haematol. 2020. PMID: 32340017 Review.
Light chain (AL) amyloidosis may present with highly specific signs such as macroglossia and periorbital purpura, but these signs are insensitive. ...All MGUS patients should be routinely screened for AL amyloidosis by a focused history a
Light chain (AL) amyloidosis may present with highly specific signs such as macroglossia and periorbital purpura
Cardiac amyloidosis.
Martinez-Naharro A, Hawkins PN, Fontana M. Martinez-Naharro A, et al. Clin Med (Lond). 2018 Apr 1;18(Suppl 2):s30-s35. doi: 10.7861/clinmedicine.18-2-s30. Clin Med (Lond). 2018. PMID: 29700090 Free PMC article. Review.
The need for a high index of suspicion and the critical importance of precise biochemical typing of the amyloid deposits is paramount in light of recent therapeutic advances that can significantly improve prognosis. Most cases of cardiac amyloidosis are of either transthyr …
The need for a high index of suspicion and the critical importance of precise biochemical typing of the amyloid deposits is paramount in lig …
Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
Ruberg FL, Maurer MS. Ruberg FL, et al. JAMA. 2024 Mar 5;331(9):778-791. doi: 10.1001/jama.2024.0442. JAMA. 2024. PMID: 38441582 Review.
IMPORTANCE: Systemic amyloidosis from transthyretin (ATTR) protein is the most common type of amyloidosis that causes cardiomyopathy. ...The diagnosis can be made using serum free light chain assay and immunofixation electrophoresis to exclude light
IMPORTANCE: Systemic amyloidosis from transthyretin (ATTR) protein is the most common type of amyloidosis that causes cardiomy …
AL amyloidosis: advances in diagnostics and treatment.
Ryšavá R. Ryšavá R. Nephrol Dial Transplant. 2019 Sep 1;34(9):1460-1466. doi: 10.1093/ndt/gfy291. Nephrol Dial Transplant. 2019. PMID: 30299492 Review.
AL amyloidosis (light chain; previously also called primary amyloidosis) is a systemic disease characterized by an amyloid deposition process affecting many organs, and which still has unsatisfactory survival of patients. ...AL amyloid
AL amyloidosis (light chain; previously also called primary amyloidosis) is a systemic disease characteri
Cardiac Amyloidosis.
Gertz MA. Gertz MA. Heart Fail Clin. 2022 Jul;18(3):479-488. doi: 10.1016/j.hfc.2022.02.005. Heart Fail Clin. 2022. PMID: 35718420 Free PMC article. Review.
In cardiology, the 2 most common subunits accounting for well more than 90% of cardiac amyloidosis are either immunoglobulin light chain, amyloid light-chain (AL) amyloidosis, or transthyretin; transthyretin (TTR) amyloid
In cardiology, the 2 most common subunits accounting for well more than 90% of cardiac amyloidosis are either immunoglobulin
Daratumumab in AL amyloidosis.
Wechalekar AD, Sanchorawala V. Wechalekar AD, et al. Blood. 2022 Dec 1;140(22):2317-2322. doi: 10.1182/blood.2021014613. Blood. 2022. PMID: 35507692 Free article. Review.
Light-chain amyloidosis has come far, with the first treatment getting regulatory approval in 2021. ...Early identification, correct fibril typing, challenges of the very advanced patient, and lack of therapies to remove amyloid deposits remain under study, b
Light-chain amyloidosis has come far, with the first treatment getting regulatory approval in 2021. ...Early identifica
Comprehensive Review of AL amyloidosis: some practical recommendations.
Al Hamed R, Bazarbachi AH, Bazarbachi A, Malard F, Harousseau JL, Mohty M. Al Hamed R, et al. Blood Cancer J. 2021 May 18;11(5):97. doi: 10.1038/s41408-021-00486-4. Blood Cancer J. 2021. PMID: 34006856 Free PMC article. Review.
Amyloid light chain (AL) amyloidosis is among the more common and more severe of the amyloidoses usually involving the slow proliferation of a bone-marrow-residing plasma cell (PC) clone and the secretion of unstable immunoglobulin-free light ch …
Amyloid light chain (AL) amyloidosis is among the more common and more severe of the amyloidoses usually involvi …
Systemic AL amyloidosis: current approach and future direction.
Bou Zerdan M, Nasr L, Khalid F, Allam S, Bouferraa Y, Batool S, Tayyeb M, Adroja S, Mammadii M, Anwer F, Raza S, Chaulagain CP. Bou Zerdan M, et al. Oncotarget. 2023 Apr 26;14:384-394. doi: 10.18632/oncotarget.28415. Oncotarget. 2023. PMID: 37185672 Free PMC article. Review.
Systemic Light chain (AL) amyloidosis is a monoclonal plasma cell proliferative disorder characterized by deposition of amyloidogenic monoclonal light chain fragments causing organ dysfunction. ...While it is widely accepted that the pati …
Systemic Light chain (AL) amyloidosis is a monoclonal plasma cell proliferative disorder characterized by deposi …
902 results